Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 11:37 PM
Ignite Modification Date: 2025-12-24 @ 11:37 PM
NCT ID: NCT05332756
Eligibility Criteria: Inclusion Criteria: 1. Patients with age between 2-60 years; 2. A clinical diagnosis of moyamoya disease, including unilateral and bilateral disease. 3. Patients are medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation. 4. Capable of understanding the purpose and risk of the study and has signed the informed consent. If the participant is not capable of this at the time of enrollment, a legally authorized representative will provide written informed consent in accordance with all regulations. 5. Ability to comply with study follow-up. Exclusion Criteria: 1. Concomitant other diseases, including systemic vasculitis, neurofibroma, meningitis, sickle cell disease, down's syndrome, and previous basilar radiotherapy. 2. Patients with cardiogenic embolism, including a history of atrial fibrillation, valvular disease or cardiac valve replacement. 3. Patients are allergic to the contrast agents. 4. Patients are treated with direct, indirect, or combined revascularization depending on the presentation. 5. Physical or subjective failure to cooperate with the examination or serious comorbid diseases. 6. Patients are unable or unlikely to return for follow-up visits. 7. Any other reasons that, in the opinion of the investigators, make the participant unsuitable for enrollment.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 2 Years
Maximum Age: 60 Years
Study: NCT05332756
Study Brief:
Protocol Section: NCT05332756